If you have looked for standalone TB-500 at telos rx and not found it, there is a specific, honest reason. It is worth understanding rather than guessing at.
telos rx does not sell standalone TB-500 because the FDA classified it as a Category 2 bulk substance in late 2023, restricting compounding pharmacies from preparing it alone. A BPC-157 plus TB-500 combination protocol is available instead.
Start the BPC-157 + TB-500 combo intake →The direct answer
telos rx does not sell TB-500 alone due to its FDA Category 2 bulk substance classification from late 2023. That classification restricts partner compounding pharmacies from preparing or dispensing TB-500 as a standalone product, regardless of what an individual provider might otherwise recommend.
This is not a business decision about demand or pricing. It is a regulatory constraint that applies to the substance itself when compounded on its own, across the compounding industry generally, not specific to telos rx.
What Category 2 means for a compounding pharmacy
Compounding pharmacies operate within a framework that sorts bulk drug substances into categories, based on the FDA's assessment of available safety information. Category 2 substances are ones the agency has flagged as not currently appropriate for standalone compounding, pending further review.
A pharmacy that continued to compound a Category 2 substance as a standalone product would be operating outside that framework. telos rx works only with partner compounding pharmacies that stay within current regulatory guidance. That is part of why standalone TB-500 is not something telos rx offers.
What is different about the combination protocol
telos rx does offer a BPC-157 plus TB-500 combination protocol, available through the BPC-157 + TB-500 combination page. This combination is reviewed and prepared as its own distinct formulation. It sits on different regulatory footing than TB-500 sold alone.
It is reasonable to wonder why one is available and the other is not. The short explanation is that Category 2 status specifically targets TB-500 as an isolated bulk substance. A combination formulation is evaluated separately from that specific restriction.
What this is not
This is not a claim that TB-500 has been proven unsafe, and it is not telos rx's independent judgment about the peptide. It is a description of a current regulatory classification that applies broadly, not something specific to telos rx's own policies or preferences.
It is also not a signal that availability is imminent. telos rx does not have, and does not claim to have, a timeline for when or whether this classification might change in the future.
Why this kind of restriction exists at all
Compounding regulation exists to give patients some assurance that a prepared medication meets baseline standards. Compounded products are not individually FDA-approved the way manufactured drugs are. Category classifications are one tool the FDA uses to manage that oversight across many nominated substances at once.
Without some system of review, compounding pharmacies would have far less guidance about which bulk substances raise open safety questions. The categories are imperfect, and they change as new information becomes available, but they exist to give both pharmacies and patients a consistent reference point.
Understanding this larger purpose can make an individual restriction, like the one on TB-500, feel less like an arbitrary inconvenience and more like part of a broader, ongoing safety process.
What to do if standalone TB-500 was specifically what you wanted
If your interest was in TB-500 by itself, rather than the combination, it is worth being direct with yourself about that. The combination protocol is a different product with a different formulation. It should be considered on its own merits with a licensed provider, rather than as a workaround.
If you are open to exploring what is actually available, a conversation with a telos rx provider about the BPC-157 plus TB-500 combination or about standalone BPC-157 is a reasonable next step.
How telos rx decides which peptides to offer
telos rx's compounded peptide program is built around what partner compounding pharmacies can legally and safely prepare at a given time. That means the list of available products changes as regulatory guidance changes, not on a fixed schedule set by telos rx alone.
This is different from a typical retail catalog, where a product is simply added when demand justifies it. Availability here is gated first by regulatory status, then by clinical review, and only then by patient demand. TB-500 currently fails the first gate as a standalone product.
Other peptides discussed in research and recovery communities may be in a similar position, available only in combination formulations, or not currently offered at all, depending on their own individual regulatory status.
What patients can reasonably expect going forward
telos rx updates its product pages when a substance's status changes, rather than leaving outdated information live. If standalone TB-500 ever becomes available through a legitimate compounding pathway, that would be reflected on the relevant pages directly.
Until then, patients researching TB-500 have an accurate, current answer rather than a vague one. Standalone TB-500 is not offered. The BPC-157 plus TB-500 combination protocol is. That is the honest state of things today, and it is worth building any decision around that fact rather than around speculation.
Why honesty matters more than a quick sale
Some marketing pages online blur the line between what a peptide is studied for and what is actually available to order. A confident-sounding page tends to convert better than an honest one. telos rx takes a different approach in this wave of educational content.
Stating plainly that a substance is not currently offered, and explaining the actual regulatory reason, costs a potential sale in the short term. It also means a patient reading this article can trust what it says, rather than wondering whether the page is quietly overselling something that is not really there.
That same standard applies to the BPC-157 plus TB-500 combination protocol. It is described as what it is, a distinct, reviewed formulation, not as standalone TB-500 with a different label attached to it.
A brief note on how to weigh secondhand information
Recovery and research communities online are a mix of genuinely informed contributors and confident-sounding guesswork. Both can look similar at a glance, especially in a forum thread or a comment section without named sources.
When you read a claim about TB-500's availability, ask where it comes from and how recent it is. A claim tied to a specific, checkable fact, like a named FDA classification and a date, is easier to verify than a vague assertion that a peptide is easy to get somewhere.
This article ties its claims to a specific classification you can look up yourself, rather than asking you to simply trust the source. That is a habit worth applying to any health-related claim you encounter online, whether it involves TB-500 or an entirely different substance.
A licensed provider is also a resource here. If you read something online about TB-500 that this article does not address, raising it during an intake conversation is a reasonable way to get a direct, individualized answer.
Where to read more, from primary sources
For general background on how the FDA approaches compounding oversight, see the FDA's compounding questions and answers page. For published research involving thymosin beta-4, the natural protein TB-500 is derived from, see this PubMed search of the current literature. Reading primary sources directly is a better habit than relying on secondhand summaries, especially for a peptide whose regulatory status and research base are both still evolving.
Frequently Asked Questions
Is telos rx choosing not to sell TB-500, or is it restricted?
It is restricted, not a choice telos rx made independently. The FDA classified TB-500 as a Category 2 bulk substance in late 2023, which limits what partner compounding pharmacies can prepare as a standalone product. That limit applies regardless of any individual clinic's own preference or business interest.
Does every clinic follow this restriction?
A licensed compounding pharmacy operating within current FDA guidance should follow it. telos rx works only with partner pharmacies that stay within that framework, which is part of how telos rx maintains its LegitScript certification and patient trust.
Can I still get TB-500 through the combination protocol?
Only as part of the BPC-157 plus TB-500 combination, which is a distinct, separately reviewed formulation, not standalone TB-500 dispensed on its own.
Does this mean TB-500 is dangerous?
It means the FDA currently classifies it in a way that restricts standalone compounding pending further review. That is a regulatory status, not a conclusion about safety that telos rx is positioned to make on its own behalf.
Will telos rx offer standalone TB-500 eventually?
There is no confirmed timeline. telos rx describes its current status accurately rather than speculating about future changes, and will update its pages promptly if the status ever changes.
What should I ask my provider if I am interested in this peptide?
Ask specifically about the BPC-157 plus TB-500 combination protocol and whether it fits your goals and history. That is the product currently available, and a provider can walk through it with you in detail, including how it differs from standalone TB-500.
telos rx is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations by partner compounding pharmacies. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Questions about the BPC-157 + TB-500 combination protocol? Message the telos rx care team or read more on the BPC-157 + TB-500 combination page.